Showing 6171-6180 of 9509 results for "".
- Allergan Acquires Topokine Therapeuticshttps://practicaldermatology.com/news/allergan-acquires-topokine-therapeutics/2458596/Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokin
- Personalized Medicine In Action: New Biomarker May Pinpoint Aggressive BCChttps://practicaldermatology.com/news/personalized-medicine-in-action-new-biomarker-may-pinpoint-aggressive-bcc/2458598/A biomarker associated with basal cell carcinoma around the eye may help signal which tumors are likely to be aggressive, report researchers from University of Michigan (U-M) at Ann Arbor. The findings, which appear in JAMA Oncology, may help eliminat
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq
- Shay Mitchell Signs on as Brand Ambassador for Bioré's New Baking Soda Cleansershttps://practicaldermatology.com/news/shay-mitchell-signs-on-as-brand-ambassador-for-biors-new-baking-soda-cleansers/2458619/Actress Shay Mitchell is the face of Bioré® for 2016, and will be featured in upcoming campaigns for the brand’s new Baking Soda cleansers. Mitchell will help launch The Bioré® Baking Soda Pore Cleanser an